About: http://data.cimple.eu/news-article/5ea2e78220fc3abe591ff53496a21fa7b715b4f3e5d067976c94db2f     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Swiss regulators said Wednesday that data submitted by AstraZeneca were not sufficient for it to authorise use of the Anglo-Swedish firm's Covid-19 vaccine and "new studies" were needed. The Swissmedic regulatory authority said it had been examining information from AstraZeneca but that was "not yet sufficient to permit authorisation". "To obtain more information about safety, efficacy and quality, additional data from new studies are needed," it said in a statement. Switzerland has so far given the green light to Covid-19 vaccines made by Pfizer-BioNTech and Moderna. It had been expected to authorise the AstraZeneca jab soon, after the neighbouring European Union last week gave the vaccine the go ahead. But while the EU granted approval for use in all people over the age of 18, several European countries have advised against giving the jabs to people over 65, citing lack of evidence that it was effective among the elderly. Swissmedic said a meeting of its external advisory body on Tuesday had confirmed its interim assessment of the AstraZeneca vaccine data. "The data currently available do not point to a positive decision regarding benefits and risks," it said. "To obtain a conclusive assessment, the applicant will among other things have to submit additional efficacy data from a Phase 3 trial under way in North and South America, and these will have to be analysed. "As soon as the results have been received, a temporary authorisation according to the rolling procedure could be issued at very short notice," it added. Switzerland, which kicked off vaccination against the deadly coronavirus in late December, meanwhile announced Wednesday that it had signed three more contracts to acquire another 17 million vaccine doses. The country of 8.5 million people said it had reached an agreement with Germany's Curevac, whose vaccine is in Phase 3 trials, and the Swedish government for the delivery of five million doses. It said it had also signed a preliminary agreement with US firm Novavax for six million doses. These will add two new vaccines to the Swiss portfolio, if they are approved by regulators. At the same time, the Swiss government had also signed a deal to acquire an additional six million doses of the Moderna vaccine, bringing the total number of those jabs available in Switzerland to 13.5 million. In addition, the government has signed deals for access to around three million Pfizer-BioNTech doses and 5.3 million AstraZeneca doses. nl/rjm/bp
schema:headline
  • Swiss say more data needed on AstraZeneca jab
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
http://data.cimple...entionsConspiracy
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software